{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:56:59Z","timestamp":1787003819541,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1903304, 82160169, 82460175"],"award-info":[{"award-number":["U1903304, 82160169, 82460175"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Key Program of Natural Science Foundation of Xinjiang Uygur Autonomous Region","award":["2022D01D16"],"award-info":[{"award-number":["2022D01D16"]}]},{"name":"Tianshan Innovative Research Team Plan","award":["2024D14011"],"award-info":[{"award-number":["2024D14011"]}]},{"name":"Xinjiang Uygur Autonomous Region Tianshan Youth Science and Technology Elite Talent Project","award":["2022TSYCCX0031, 2023TSYCQNTJ0027"],"award-info":[{"award-number":["2022TSYCCX0031, 2023TSYCQNTJ0027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91061-5","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T09:02:01Z","timestamp":1740560521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["PCSK9 with a gain of function D374Y mutation aggravates atherosclerosis by inhibiting PPAR\u03b1 expression"],"prefix":"10.1038","volume":"15","author":[{"given":"Yuan feng","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao cui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuoluonayi","family":"Mijiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abidan","family":"Abudurusuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li hui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangdang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"issue":"11","key":"91061_CR1","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.2538","volume":"17","author":"C Weber","year":"2011","unstructured":"Weber, C. et al. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 17 (11), 1410\u20131422 (2011).","journal-title":"Nat. Med."},{"issue":"11","key":"91061_CR2","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1161\/ATVBAHA.114.304488","volume":"34","author":"GE Raskob","year":"2014","unstructured":"Raskob, G. E. et al. Thrombosis: a major contributor to global disease burden. Arterioscler. Thromb. Vasc Biol. 34 (11), 2363\u20132371 (2014).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"5","key":"91061_CR3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/cvr\/cvz313","volume":"116","author":"Z Ding","year":"2020","unstructured":"Ding, Z. et al. PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1. Cardiovasc. Res. 116 (5), 908\u2013915 (2020).","journal-title":"Cardiovasc. Res."},{"issue":"7855","key":"91061_CR4","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby, P. The changing landscape of atherosclerosis. Nature 592 (7855), 524\u2013533 (2021).","journal-title":"Nature"},{"key":"91061_CR5","doi-asserted-by":"publisher","first-page":"101109","DOI":"10.1016\/j.plipres.2021.101109","volume":"83","author":"H Li","year":"2021","unstructured":"Li, H. et al. Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis. Prog Lipid Res. 83, 101109 (2021).","journal-title":"Prog Lipid Res."},{"issue":"10","key":"91061_CR6","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.cgh.2019.12.026","volume":"18","author":"F Baratta","year":"2020","unstructured":"Baratta, F. et al. Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin. Gastroenterol. Hepatol. 18 (10), 2324\u20132331 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"22","key":"91061_CR7","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/eurheartj\/ehv759","volume":"37","author":"D Tousoulis","year":"2016","unstructured":"Tousoulis, D. et al. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur. Heart J. 37 (22), 1723\u20131732 (2016).","journal-title":"Eur. Heart J."},{"issue":"47","key":"91061_CR8","doi-asserted-by":"publisher","first-page":"48865","DOI":"10.1074\/jbc.M409699200","volume":"279","author":"S Benjannet","year":"2004","unstructured":"Benjannet, S. et al. NARC-1\/PCSK9 and its natural Mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279 (47), 48865\u201348875 (2004).","journal-title":"J. Biol. Chem."},{"issue":"4","key":"91061_CR9","doi-asserted-by":"publisher","first-page":"e13459","DOI":"10.1111\/eci.13459","volume":"51","author":"R Ragusa","year":"2021","unstructured":"Ragusa, R. et al. PCSK9 and atherosclerosis: looking beyond LDL regulation. Eur. J. Clin. Invest. 51 (4), e13459 (2021).","journal-title":"Eur. J. Clin. Invest."},{"issue":"9","key":"91061_CR10","doi-asserted-by":"publisher","first-page":"909","DOI":"10.5551\/jat.55400","volume":"27","author":"E Yurtseven","year":"2020","unstructured":"Yurtseven, E. et al. An update on the role of PCSK9 in atherosclerosis. J. Atheroscler Thromb. 27 (9), 909\u2013918 (2020).","journal-title":"J. Atheroscler Thromb."},{"key":"91061_CR11","doi-asserted-by":"publisher","first-page":"764038","DOI":"10.3389\/fcvm.2021.764038","volume":"8","author":"XD Xia","year":"2021","unstructured":"Xia, X. D. et al. Regulation of PCSK9 expression and function: mechanisms and therapeutic implications. Front. Cardiovasc. Med. 8, 764038 (2021).","journal-title":"Front. Cardiovasc. Med."},{"issue":"2","key":"91061_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34 (2), 154\u2013156 (2003).","journal-title":"Nat. Genet."},{"issue":"7","key":"91061_CR13","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.111.057406","volume":"125","author":"M Denis","year":"2012","unstructured":"Denis, M. et al. Gene inactivation of proprotein convertase subtilisin\/kexin type 9 reduces atherosclerosis in mice. Circulation 125 (7), 894\u2013901 (2012).","journal-title":"Circulation"},{"issue":"3","key":"91061_CR14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1086\/507488","volume":"79","author":"Z Zhao","year":"2006","unstructured":"Zhao, Z. et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79 (3), 514\u2013523 (2006).","journal-title":"Am. J. Hum. Genet."},{"key":"91061_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","volume":"262","author":"ZH Tang","year":"2017","unstructured":"Tang, Z. H. et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-\u03baB pathway. Atherosclerosis 262, 113\u2013122 (2017).","journal-title":"Atherosclerosis"},{"issue":"6294","key":"91061_CR16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/347645a0","volume":"347","author":"I Issemann","year":"1990","unstructured":"Issemann, I. et al. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (6294), 645\u2013650 (1990).","journal-title":"Nature"},{"issue":"8","key":"91061_CR17","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.bbamcr.2010.03.013","volume":"1803","author":"M Islinger","year":"2010","unstructured":"Islinger, M. et al. Be different\u2013the diversity of peroxisomes in the animal Kingdom. Biochim. Biophys. Acta. 1803 (8), 881\u2013897 (2010).","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"91061_CR18","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3803\/EnM.2021.1100","volume":"36","author":"Y Lee","year":"2021","unstructured":"Lee, Y. et al. The effects of Ppar agonists on atherosclerosis and nonalcoholic fatty liver disease in ApoE-\/-FXR-\/- mice. Endocrinol. Metab. (Seoul). 36 (6), 1243\u20131253 (2021).","journal-title":"Endocrinol. Metab. (Seoul)"},{"issue":"4","key":"91061_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1172\/JCI10370","volume":"106","author":"AC Li","year":"2000","unstructured":"Li, A. C. et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106 (4), 523\u2013531 (2000).","journal-title":"J. Clin. Invest."},{"issue":"8","key":"91061_CR20","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.bbalip.2007.04.021","volume":"1771","author":"F Zandbergen","year":"2007","unstructured":"Zandbergen, F. et al. PPAR\u03b1lpha in atherosclerosis and inflammation. Biochim. Biophys. Acta. 1771 (8), 972\u2013982 (2007).","journal-title":"Biochim. Biophys. Acta"},{"issue":"10","key":"91061_CR21","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1111\/1440-1681.12453","volume":"42","author":"BD Chen","year":"2015","unstructured":"Chen, B. D. et al. Targeting transgene to the heart and liver with AAV9 by different promoters. Clin. Exp. Pharmacol. Physiol. 42 (10), 1108\u20131117 (2015).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"2","key":"91061_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/cvr\/cvw053","volume":"110","author":"H Tavori","year":"2016","unstructured":"Tavori, H. et al. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovasc. Res. 110 (2), 268\u2013278 (2016).","journal-title":"Cardiovasc. Res."},{"key":"91061_CR23","first-page":"e52749","volume":"98","author":"A Layoun","year":"2015","unstructured":"Layoun, A. et al. Isolation of murine peritoneal macrophages to carry out gene expression analysis upon Toll-like receptors stimulation. J. Vis. Exp. 98, e52749 (2015).","journal-title":"J. Vis. Exp."},{"issue":"1","key":"91061_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bbrc.2019.03.008","volume":"512","author":"MH Sun","year":"2019","unstructured":"Sun, M. H. et al. Cardioprotective effects of constitutively active MEK1 against H2O2-induced apoptosis and autophagy in cardiomyocytes via the ERK1\/2 signaling pathway. Biochem. Biophys. Res. Commun. 512 (1), 125\u2013130 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"91061_CR25","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","volume":"135","author":"G Reyes-Soffer","year":"2017","unstructured":"Reyes-Soffer, G. et al. Effects of PCSK9 Inhibition with Alirocumab on lipoprotein metabolism in healthy humans. Circulation 135 (4), 352\u2013362 (2017).","journal-title":"Circulation"},{"key":"91061_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.bbrc.2022.07.031","volume":"622","author":"M Xu","year":"2022","unstructured":"Xu, M. et al. A novel mouse model of diabetes, atherosclerosis and fatty liver disease using an AAV8-PCSK9-D377Y injection and dietary manipulation in Db\/db mice. Biochem. Biophys. Res. Commun. 622, 163\u2013169 (2022).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"91061_CR27","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1161\/ATVBAHA.110.204040","volume":"30","author":"B Herbert","year":"2010","unstructured":"Herbert, B. et al. Increased secretion of lipoproteins in Transgenic mice expressing human D374Y PCSK9 under physiological genetic control. Arterioscler. Thromb. Vasc Biol. 30 (7), 1333\u20131339 (2010).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"11","key":"91061_CR28","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1194\/jlr.M053207","volume":"55","author":"B Ason","year":"2014","unstructured":"Ason, B. et al. PCSK9 Inhibition fails to alter hepatic LDLR, Circulating cholesterol, and atherosclerosis in the absence of ApoE. J. Lipid Res. 55 (11), 2370\u20132379 (2014).","journal-title":"J. Lipid Res."},{"issue":"12","key":"91061_CR29","doi-asserted-by":"publisher","first-page":"100296","DOI":"10.1016\/j.jlr.2022.100296","volume":"63","author":"M Mobilia","year":"2022","unstructured":"Mobilia, M. et al. Dennd5b-Deficient mice are resistant to PCSK9-Induced hypercholesterolemia and Diet-Induced hepatic steatosis. J. Lipid Res. 63 (12), 100296 (2022).","journal-title":"J. Lipid Res."},{"key":"91061_CR30","doi-asserted-by":"publisher","first-page":"155774","DOI":"10.1016\/j.metabol.2023.155774","volume":"152","author":"Z Chen","year":"2024","unstructured":"Chen, Z. et al. Inhibition of PCSK9 prevents and alleviates cholesterol gallstones through PPAR\u03b1-mediated CYP7A1 activation. Metabolism 152, 155774 (2024).","journal-title":"Metabolism"},{"issue":"4900","key":"91061_CR31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1126\/science.2565046","volume":"244","author":"D Gavish","year":"1989","unstructured":"Gavish, D. et al. Heritable allele-specific differences in amounts of ApoB and low-density lipoproteins in plasma. Science 244 (4900), 72\u201376 (1989).","journal-title":"Science"},{"issue":"6","key":"91061_CR32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJMp1106688","volume":"365","author":"AB Goldfine","year":"2011","unstructured":"Goldfine, A. B. et al. Fibrates in the treatment of dyslipidemias\u2013time for a reassessment. N Engl. J. Med. 365 (6), 481\u2013484 (2011).","journal-title":"N Engl. J. Med."},{"issue":"7","key":"91061_CR33","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","volume":"65","author":"A Montagner","year":"2016","unstructured":"Montagner, A. et al. Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut 65 (7), 1202\u20131214 (2016).","journal-title":"Gut"},{"issue":"5","key":"91061_CR34","doi-asserted-by":"publisher","first-page":"R733","DOI":"10.1152\/ajpregu.00153.2019","volume":"317","author":"DE Stec","year":"2019","unstructured":"Stec, D. E. et al. Loss of hepatic PPAR\u03b1 promotes inflammation and plasma hyperlipidemia in diet-induced obesity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 317 (5), R733\u2013R745 (2019).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"11","key":"91061_CR35","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1172\/JCI18730","volume":"114","author":"AC Li","year":"2004","unstructured":"Li, A. C. et al. Differential Inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR\u03b1lpha, beta\/delta, and gamma. J. Clin. Invest. 114 (11), 1564\u20131576 (2004).","journal-title":"J. Clin. Invest."},{"issue":"1","key":"91061_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11883-024-01267-7","volume":"27","author":"N Punnanithinont","year":"2024","unstructured":"Punnanithinont, N. et al. Anti-inflammatory therapies in Atherosclerosis - Where are we going? Curr. Atheroscler Rep. 27 (1), 19 (2024).","journal-title":"Curr. Atheroscler Rep."},{"issue":"18","key":"91061_CR37","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","volume":"70","author":"P Libby","year":"2017","unstructured":"Libby, P. Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of cantos and beyond. J. Am. Coll. Cardiol. 70 (18), 2278\u20132289 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"16","key":"91061_CR38","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.7150\/thno.45939","volume":"10","author":"Z Ding","year":"2020","unstructured":"Ding, Z. et al. NLRP3 inflammasome via IL-1\u03b2 regulates PCSK9 secretion. Theranostics 10 (16), 7100\u20137110 (2020).","journal-title":"Theranostics"},{"issue":"1","key":"91061_CR39","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","volume":"8","author":"C Ricci","year":"2018","unstructured":"Ricci, C. et al. PCSK9 induces a pro-inflammatory response in macrophages. Sci. Rep. 8 (1), 2267 (2018).","journal-title":"Sci. Rep."},{"issue":"4","key":"91061_CR40","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3892\/ijmm.2012.1072","volume":"30","author":"Z Tang","year":"2012","unstructured":"Tang, Z. et al. PCSK9 SiRNA suppresses the inflammatory response induced by OxLDL through Inhibition of NF-\u03baB activation in THP-1-derived macrophages. Int. J. Mol. Med. 30 (4), 931\u2013938 (2012).","journal-title":"Int. J. Mol. Med."},{"issue":"8","key":"91061_CR41","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/cvr\/cvy079","volume":"114","author":"Z Ding","year":"2018","unstructured":"Ding, Z. et al. PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages. Cardiovasc. Res. 114 (8), 1145\u20131153 (2018).","journal-title":"Cardiovasc. Res."},{"issue":"50","key":"91061_CR42","doi-asserted-by":"publisher","first-page":"48051","DOI":"10.1074\/jbc.M206966200","volume":"277","author":"H Duez","year":"2002","unstructured":"Duez, H. et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist Fenofibrate in mice. J. Biol. Chem. 277 (50), 48051\u201348057 (2002).","journal-title":"J. Biol. Chem."},{"issue":"2","key":"91061_CR43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1161\/01.CIR.103.2.213","volume":"103","author":"N Marx","year":"2001","unstructured":"Marx, N. et al. PPAR\u03b1lpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 103 (2), 213\u2013219 (2001).","journal-title":"Circulation"},{"issue":"8","key":"91061_CR44","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1194\/jlr.M800542-JLR200","volume":"50","author":"Y Luo","year":"2009","unstructured":"Luo, Y. et al. Function and distribution of Circulating human PCSK9 expressed extrahepatically in Transgenic mice. J. Lipid Res. 50 (8), 1581\u20131588 (2009).","journal-title":"J. Lipid Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91061-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91061-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91061-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T09:26:06Z","timestamp":1740561966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91061-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91061"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91061-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"8 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6941"}}